Spero Therapeutics to Report Q4 and FY25 Financials on March 26, 2026

miércoles, 18 de marzo de 2026, 4:07 pm ET1 min de lectura
SPRO--

Spero Therapeutics will report Q4 and full-year 2025 financial results and provide a business update on March 26, 2026. The company will not host a conference call. Spero Therapeutics is a clinical-stage biopharmaceutical company focused on rare diseases and high unmet need.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios